The news: The Trump administration is following through on last year's pledge to get rid of a regulatory provision that allows pharma companies to omit full product safety warnings from direct-to-consumer (D2C) prescription drug ads.

The administration's recently released 2026 regulatory agenda includes a proposed rule, "Transparency in Direct-to-Consumer Advertising," slated for publication in December. The regulation would require prescription drug ads to include all product side effects and contraindications within the ad itself, rather than directing consumers to an external source, such as a website or 1-800 number for that information.

The rule’s abstract (which is all that’s currently available) does not specify whether it would apply to prescription drug ads on digital channels such as social media. It specifically references ads broadcast on radio and television since the prior regulation was meant for the pre-digital era.

Why it matters: Pharma companies and their agency partners were relieved when Trump's memorandum last year didn't immediately move forward, easing fears that drug ads would need to be overhauled to comply with the proposed requirement. Although the FDA has sharply increased warning and enforcement letters over allegedly misleading drug advertising across TV and digital channels, those compliance changes have been relatively manageable.

Now, drugmakers' concerns about having to significantly rework their ads have resurfaced. The changes the proposal would require, especially for TV drug ads, are substantial enough that 4As Health called the FDA's planned rule a "de facto ban" on D2C prescription drug advertising.

The adequate provision standard has long allowed most TV drug ads to run roughly 60 seconds because they aren't required to include the full safety and side effect information found in a product's labeling. If the rule is finalized, pharma marketers will have to consider whether to increase advertising budgets, as significantly longer commercials could require purchasing substantially more airtime. The abstract of the proposal explicitly acknowledged that it would have an economically significant impact.

Implications for pharma marketers: The proposal isn’t guaranteed to be released on schedule and, if it is, will almost certainly face legal challenges and broad industry opposition.

Still, drug companies should view this as the first meaningful step beyond last year's announcement, signaling the administration's intent to follow through on its goal. The absence of any follow-up proposed regulation after last year's announcement likely explains why drugmakers have not yet materially adjusted their TV ad spending, per iSpot data. (TV is the channel most exposed to a disclosure rule because of its high costs and limited flexibility).

Industry response could be different this time. Pharma companies are likely to focus first on mounting legal challenges and coordinating an industry response to the forthcoming rule, arguing that D2C advertising benefits patients rather than immediately reworking their campaigns, and that their commercials already include a clear major statement of key risks and side effects.

Longer term, however, the proposal could accelerate a broader rethink of D2C marketing strategy. We forecast that pharma marketers will continue shifting ad budgets toward digital channels while steadily reducing spending on traditional media, a trend that would likely accelerate if TV ads become more cumbersome. More investment could shift to flexible digital channels, particularly social media platforms like YouTube, where consumers increasingly turn for health information and advertisers aren't constrained by traditional TV ad lengths.